FDA Approves Drug Targeting Johns Hopkins-Discovered Brain Cancer Gene Mutation
A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center.
LEARN MORE
SEE ALL NEWS
Recent Posts
5 Healthy Habits That Help During Cancer Treatment
Understanding Mammogram Results
A 19-Year Fight Against Prostate Cancer Brings Man to Johns Hopkins Medicine
Scientists Advance Efforts to Create ‘Virtual Cell Lab’ As Testing Ground for Future Research with Live Cells
Ultra-Processed Foods: Q&A with 2 Dietitians
Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers
‘Power Surges’ on Cancer Cell Membranes May Fuel Progression of Disease
New Cancer Target Discovered
How surgeons build a new bladder for cancer patients like Deion Sanders